Unique Breast Cancer Drug Approved; Cymbalta OK'd for Juvenile Fibromyalgia

Inbox

x

MPR Daily Dose <editor@email.empr.com> Unsubscribe

Fri, Apr 24, 3:02 AM (1 day ago)

to me

5 of 6

Unique Breast Cancer Drug Approved; Cymbalta OK'd for Juvenile Fibromyalgia

Inbox

x

MPR Daily Dose <editor@email.empr.com> Unsubscribe

Fri, Apr 24, 3:02 AM (1 day ago)

to me

If you are having trouble viewing this email, click here.

MUST READS FDA Approves First Antibody-Drug Conjugate for Metastatic Triple-Negative Breast Cancer Cymbalta Approved for Pediatric Patients With Fibromyalgia Imbruvica Plus Rituximab Approved for Chronic Lymphocytic Leukemia Inspire Therapy Approved for Younger Patients With Obstructive Sleep Apnea Daridorexant Improves Sleep, Daytime Performance in Insomnia Study COVID-19 Resource Center Featured Content Collection and Use of Real-World Data Continues to Grow Around the World CME/CE Spotlight Acute Management of Migraine: Best Practices in Assessment and Diagnosis AMA PRA Category 1 Credit(s)TM, AAFP Prescribed Credit CLICK HERE FOR A FULL LIST OF COURSES CE/CME Powered By myCME

If you are having trouble viewing this email, click here.

MUST READS FDA Approves First Antibody-Drug Conjugate for Metastatic Triple-Negative Breast Cancer Cymbalta Approved for Pediatric Patients With Fibromyalgia Imbruvica Plus Rituximab Approved for Chronic Lymphocytic Leukemia Inspire Therapy Approved for Younger Patients With Obstructive Sleep Apnea Daridorexant Improves Sleep, Daytime Performance in Insomnia Study COVID-19 Resource Center Featured Content Collection and Use of Real-World Data Continues to Grow Around the World CME/CE Spotlight Acute Management of Migraine: Best Practices in Assessment and Diagnosis AMA PRA Category 1 Credit(s)TM, AAFP Prescribed Credit CLICK HERE FOR A FULL LIST OF COURSES CE/CME Powered By myCME